The International Centre for Antimicrobial Resistance Solutions (ICARS) Revenue and Competitors
Employee Data
- The International Centre for Antimicrobial Resistance Solutions (ICARS) has 40 Employees.
- The International Centre for Antimicrobial Resistance Solutions (ICARS) grew their employee count by 43% last year.
The International Centre for Antimicrobial Resistance Solutions (ICARS)'s People
Name | Title | Email/Phone |
---|---|---|
1 | Head partnerships and stakeholder engagement | Reveal Email/Phone |
The International Centre for Antimicrobial Resistance Solutions (ICARS) Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | N/A | 4 | 0% | N/A | N/A |
#2 | N/A | 40 | 43% | N/A | N/A |
What Is The International Centre for Antimicrobial Resistance Solutions (ICARS)?
Imagine a world in which AMR no longer poses a threat to the health of humans and animals, the environment, global food security and economic prosperity. This is our vision at the International Centre for Antimicrobial Resistance Solutions - ICARS. ICARS provides One Health intervention and implementation research support to low- and middle-income countries (LMICs) in their efforts to prevent and mitigate AMR. \n\nThrough our activities, we enter into partnerships with LMICs to advance the implementation of their National Action Plans (NAPs). These partnerships involve projects through which we co-develop and test new solutions for AMR mitigation, translate existing evidence into action, all while supporting capacity and capability building in LMICs. Our work also extends to advocacy for the importance of Implementation Research as a means to deliver on the NAPs.
keywords:N/AN/A
Total Funding
40
Number of Employees
N/A
Revenue (est)
43%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $7.8M | 40 | 11% | N/A |
#2 | $8.1M | 40 | -7% | N/A |
#3 | $4.6M | 40 | 0% | N/A |
#4 | $6.2M | 40 | 82% | N/A |
#5 | $6.2M | 40 | 122% | N/A |